RxDoctor Payments Data

Jack Xu

Internal Medicine · Winston Salem, NCNPI 1790239101

Payments from drug & device makers

$14,391in general payments, 2019–2025

Across 163 payments — averaging $88.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$8K
  • Heartflow, Inc.$3K
  • Boston Scientific$2K
  • Novo Nordisk$238
  • Amgen$235
  • Pfizer$220
  • plus $2K from 18 others

What the payments were for

  • Travel & lodging$6,58446%
  • Food & beverage$7,39151%
  • Education$4173%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,391 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$101,683
Medicare patients
789
Services billed
1,876

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban285$237,457
JardianceEmpagliflozin225$173,077
EntrestoSacubitril/Valsartan57$53,069
OzempicSemaglutide43$44,631
XareltoRivaroxaban45$38,688
Repatha SureclickEvolocumab28$20,316
Praluent PenAlirocumab16$7,743
Metoprolol Succinate558$5,774
Nitroglycerin125$2,616
Atorvastatin Calcium333$2,547
Bumetanide42$2,190
Ezetimibe148$1,816
Isosorbide Mononitrate ErIsosorbide Mononitrate125$1,391
Ranolazine ErRanolazine15$1,338
Carvedilol238$1,310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$220$237,457285 claims
Boehringer IngelheimJardiance$194$173,077225 claims
NovartisEntresto$196$53,06957 claims
Novo NordiskOzempic$238$44,63143 claims
Johnson & JohnsonXarelto$208$38,68845 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →